Lab21 Acquisition Will Significantly Contribute to its Growth Plans

By LabMedica International staff writers
Posted on 12 Jan 2011

Lab21 Ltd. (Cambridge, UK), a specialist in personalized medicine and clinical diagnostics, has acquired Microgen Bioproducts Ltd., (Camberley, UK). The transaction provides further expansion of Lab21's distribution channel in key territories including the US, UK, Europe, and Asia.

Lab21 provides state-of-the-art diagnostic products and services; it supports blood bank screening, medical diagnostics, and drug discovery. The product division of the company manufactures immunodiagnostic kits and reagents, and is it focused on infectious diseases for the blood-banking market.

Microgen Bioproducts develops, manufactures, and commercializes diagnostic tests to identify diseases and organisms that pose a threat to human and animal health.

Graham Mullis, CEO of Lab21 said: "Microgen Bioproducts is a well established and profitable business which will significantly contribute to our growth plans in our core products division. This acquisition highlights Lab21's commitment to continuing its exciting roll-up strategy and we expect to bring other high quality acquisitions into the Group during 2011."

Related Links:
Lab21 Ltd.
Microgen Bioproducts Ltd.